发布求助
文献互助 智能选刊 最新文献

Expert Opinion on Therapeutic Patents最新文献

筛选
英文 中文
An updated patent review of TRPA1 antagonists (2020 - present). TRPA1 拮抗剂的最新专利回顾（2020 年至今）。
IF 5.4 2区 医学
Expert Opinion on Therapeutic Patents Pub Date : 2024-05-01 Epub Date: 2024-06-17 DOI: 10.1080/13543776.2024.2364798
Rosa Maria Vitale, Luciano de Petrocellis, Pietro Amodeo
{"title":"An updated patent review of TRPA1 antagonists (2020 - present).","authors":"Rosa Maria Vitale, Luciano de Petrocellis, Pietro Amodeo","doi":"10.1080/13543776.2024.2364798","DOIUrl":"10.1080/13543776.2024.2364798","url":null,"abstract":"<p><strong>Introduction: </strong>TRPA1 is a nonselective calcium channel, a member of the transient receptor potential (TRP) superfamily, also referred to as the 'irritant' receptor, being activated by pungent and noxious exogenous chemicals as well as by endogenous algogenic stimuli, to elicit pain, itching, and inflammatory conditions. For this reason, it is considered an attractive therapeutic target to treat a wide range of diseases including acute and chronic pain, itching, and inflammatory airway diseases.</p><p><strong>Areas covered: </strong>The present review covers patents on TRPA1 antagonists disclosed from 2020 to present, falling in the following main classes: i) novel therapeutic applications for known or already disclosed antagonists, ii) identification and characterization of TRPA1 antagonists from natural sources, and iii) synthesis and evaluation of novel compounds.</p><p><strong>Expert opinion: </strong>Despite the limited number of TRPA1 antagonists in clinical trials, there is an ever-growing interest on this receptor-channel as therapeutic target, mainly due to the relevant outcomes from basic research, which unveiled novel physio-pathological mechanisms where TRPA1 is believed to play a pivotal role, for example the Alzheimer's disease or ocular diseases, expanding the panel of potential therapeutic applications for TRPA1 modulators.</p>","PeriodicalId":12314,"journal":{"name":"Expert Opinion on Therapeutic Patents","volume":" ","pages":"315-332"},"PeriodicalIF":5.4,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141283388","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
PIM kinase inhibitors: an updated patent review (2016-present). PIM 激酶抑制剂：最新专利回顾（2016 年至今）。
IF 5.4 2区 医学
Expert Opinion on Therapeutic Patents Pub Date : 2024-05-01 Epub Date: 2024-06-13 DOI: 10.1080/13543776.2024.2365411
Anushka Sharma, Rahul Dubey, Shankar Gupta, Vivek Asati, Vipul Kumar, Dileep Kumar, Debarshi Kar Mahapatra, Meenakshi Jaiswal, Sanmati Kumar Jain, Sanjay Kumar Bharti
{"title":"PIM kinase inhibitors: an updated patent review (2016-present).","authors":"Anushka Sharma, Rahul Dubey, Shankar Gupta, Vivek Asati, Vipul Kumar, Dileep Kumar, Debarshi Kar Mahapatra, Meenakshi Jaiswal, Sanmati Kumar Jain, Sanjay Kumar Bharti","doi":"10.1080/13543776.2024.2365411","DOIUrl":"10.1080/13543776.2024.2365411","url":null,"abstract":"<p><strong>Introduction: </strong>PIM Kinases (PIM-1, PIM-2, and PIM-3) have been reported to play crucial role in signaling cascades that govern cell survival, proliferation, and differentiation. Over-expression of these kinases leads to hematological malignancies such as diffuse large B cell lymphomas (DLBCL), multiple myeloma, leukemia, lymphoma and prostate cancer etc. PIM kinases as biomarkers and potential therapeutic targets have shown promise toward precision cancer therapy. The selective PIM-1, PIM-2, and/or PIM-3 isoform inhibitors have shown significant results in patients with advanced stages of cancer including relapsed/refractory cancer.</p><p><strong>Areas covered: </strong>A comprehensive literature review of PIM Kinases (PIM-1, PIM-2, and PIM-3) in oncogenesis, the patented PIM kinase inhibitors (2016-Present), and their pharmacological and structural insights have been highlighted.</p><p><strong>Expert opinion: </strong>Recently, PIM kinases viz. PIM-1, PIM-2, and PIM-3 (members of the serine/threonine protein kinase family) as therapeutic targets have attracted considerable interest in oncology especially in hematological malignancies. The patented PIM kinase inhibitors comprised of heterocyclic (fused)ring structure(s) like indole, pyridine, pyrazine, pyrazole, pyridazine, piperazine, thiazole, oxadiazole, quinoline, triazolo-pyridine, pyrazolo-pyridine, imidazo-pyridazine, oxadiazole-thione, pyrazolo-pyrimidine, triazolo-pyridazine, imidazo-pyridazine, pyrazolo-quinazoline and pyrazolo-pyridine etc. showed promising results in cancer chemotherapy.</p>","PeriodicalId":12314,"journal":{"name":"Expert Opinion on Therapeutic Patents","volume":" ","pages":"365-382"},"PeriodicalIF":5.4,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141261381","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A patent review of SHP2 allosteric inhibitors (2018-present). SHP2异构抑制剂专利回顾（2018年至今）。
IF 5.4 2区 医学
Expert Opinion on Therapeutic Patents Pub Date : 2024-05-01 Epub Date: 2024-06-13 DOI: 10.1080/13543776.2024.2365410
Alessia Petrocchi, Alina Ciammaichella
{"title":"A patent review of SHP2 allosteric inhibitors (2018-present).","authors":"Alessia Petrocchi, Alina Ciammaichella","doi":"10.1080/13543776.2024.2365410","DOIUrl":"10.1080/13543776.2024.2365410","url":null,"abstract":"<p><strong>Introduction: </strong>SHP2 (Src homology region 2-containing protein tyrosine phosphatase 2) is a target of interest for cancer therapy due to its key role in the regulation of the RAS/MAPK signal transduction pathway downstream of Receptor Tyrosine Kinases (RTKs). Moreover, SHP2 can inhibit T cells via the PD-1/PD-L1 pathway. SHP2 plays a critical role in numerous physiological and pathological cellular processes, such as cell proliferation, survival, and migration.</p><p><strong>Areas covered: </strong>This review examines SHP2 allosteric inhibitors reported in patents published in Espacenet and Scifinder databases from 2018 to present. An overview of claimed structures is conducted, focusing attention on structural modifications compared to SHP099, the first described allosteric inhibitor of SHP2.</p><p><strong>Expert opinion: </strong>Multiple potent allosteric SHP2 inhibitors have been discovered, disclosed, and tested in a variety of preclinical cancer models with strong evidence of efficacy. Fifteen compounds are currently in clinical development, but none of them have been approved for marketing. Until now, long-term benefit of SHP2 inhibitors as monotherapy agents have not been demonstrated due to acquired mechanisms of resistance and/or lack of efficacy. However, combination therapies with a variety of agents, such as MEK, BRAF, EGFR, RAS-G12C and PDL-1 inhibitors, have high potential and are currently an extensive area of investigation.</p>","PeriodicalId":12314,"journal":{"name":"Expert Opinion on Therapeutic Patents","volume":" ","pages":"383-396"},"PeriodicalIF":5.4,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141261295","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Biomedical applications of prokaryotic carbonic anhydrases: an update. 原核碳酸酐酶的生物医学应用：最新进展。
IF 5.4 2区 医学
Expert Opinion on Therapeutic Patents Pub Date : 2024-05-01 Epub Date: 2024-06-11 DOI: 10.1080/13543776.2024.2365407
Clemente Capasso, Claudiu T Supuran
{"title":"Biomedical applications of prokaryotic carbonic anhydrases: an update.","authors":"Clemente Capasso, Claudiu T Supuran","doi":"10.1080/13543776.2024.2365407","DOIUrl":"10.1080/13543776.2024.2365407","url":null,"abstract":"<p><strong>Introduction: </strong>This review offers an updated perspective on the biomedical applications of prokaryotic carbonic anhydrases (CAs), emphasizing their potential as targets for drug development against antibiotic-resistant bacterial infections. A systematic review of literature from PubMed, Web of Science, and Google Scholar has been conducted to provide a comprehensive analysis.</p><p><strong>Area covered: </strong>It delves into the pivotal roles of prokaryotic CAs in bacterial metabolism and their distinctions from mammalian CAs. The review explores the diversity of CA classes in bacteria, discusses selective inhibitors targeting bacterial CAs, and explores their potential applications in biomedical research. Furthermore, it analyzes clinical trials investigating the efficacy of carbonic anhydrase inhibitors (CAIs) and patented approaches for developing antibacterial CAIs, highlighting their translational potential in creating innovative antibacterial agents.</p><p><strong>Expert opinion: </strong>Recent years have witnessed increased recognition of CA inhibition as a promising strategy against bacterial infections. Challenges persist in achieving selectivity over human isoforms and optimizing therapeutic efficacy. Structural biology techniques provide insights into unique active site architectures, guiding selective inhibitor design. The review underscores the importance of interdisciplinary collaborations, innovative drug delivery systems, and advanced drug discovery approaches in unlocking the full therapeutic potential of prokaryotic CA inhibitors. It emphasizes the significance of these efforts in addressing antibiotic resistance and improving patient outcomes.</p>","PeriodicalId":12314,"journal":{"name":"Expert Opinion on Therapeutic Patents","volume":" ","pages":"351-363"},"PeriodicalIF":5.4,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141261418","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Targeting the TGF-β signaling pathway: an updated patent review (2021–present) 靶向 TGF-β 信号通路：最新专利回顾（2021 年至今）
IF 6.6 2区 医学
Expert Opinion on Therapeutic Patents Pub Date : 2024-04-22 DOI: 10.1080/13543776.2024.2346325
Wenhao Guo, Hanwen Liu, Yong Yan, Di Wu, Hequan Yao, Kejiang Lin, Xuanyi Li
{"title":"Targeting the TGF-β signaling pathway: an updated patent review (2021–present)","authors":"Wenhao Guo, Hanwen Liu, Yong Yan, Di Wu, Hequan Yao, Kejiang Lin, Xuanyi Li","doi":"10.1080/13543776.2024.2346325","DOIUrl":"https://doi.org/10.1080/13543776.2024.2346325","url":null,"abstract":"The TGF-β signaling pathway is a complex network that plays a crucial role in regulating essential biological functions and is implicated in the onset and progression of multiple diseases. This rev...","PeriodicalId":12314,"journal":{"name":"Expert Opinion on Therapeutic Patents","volume":"18 1","pages":""},"PeriodicalIF":6.6,"publicationDate":"2024-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140636897","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
PCSK9 inhibitors: a patent review 2018-2023 PCSK9 抑制剂：2018-2023 年专利回顾
IF 6.6 2区 医学
Expert Opinion on Therapeutic Patents Pub Date : 2024-04-08 DOI: 10.1080/13543776.2024.2340569
Enrico Mario Alessandro Fassi, Andrea Citarella, Marco Albani, Erica Ginevra Milano, Laura Legnani, Carmen Lammi, Alessandra Silvani, Giovanni Grazioso
{"title":"PCSK9 inhibitors: a patent review 2018-2023","authors":"Enrico Mario Alessandro Fassi, Andrea Citarella, Marco Albani, Erica Ginevra Milano, Laura Legnani, Carmen Lammi, Alessandra Silvani, Giovanni Grazioso","doi":"10.1080/13543776.2024.2340569","DOIUrl":"https://doi.org/10.1080/13543776.2024.2340569","url":null,"abstract":"Published in Expert Opinion on Therapeutic Patents (Just accepted, 2024)","PeriodicalId":12314,"journal":{"name":"Expert Opinion on Therapeutic Patents","volume":"106 1","pages":""},"PeriodicalIF":6.6,"publicationDate":"2024-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140571068","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Biofilm and bacterial membrane vesicles: recent advances 生物膜和细菌膜囊：最新进展
IF 6.6 2区 医学
Expert Opinion on Therapeutic Patents Pub Date : 2024-04-05 DOI: 10.1080/13543776.2024.2338101
Valentina Puca, Beatrice Marinacci, Benedetta Pellegrini, Floriana Campanile, Maria Santagati, Rossella Grande
{"title":"Biofilm and bacterial membrane vesicles: recent advances","authors":"Valentina Puca, Beatrice Marinacci, Benedetta Pellegrini, Floriana Campanile, Maria Santagati, Rossella Grande","doi":"10.1080/13543776.2024.2338101","DOIUrl":"https://doi.org/10.1080/13543776.2024.2338101","url":null,"abstract":"Bacterial Membrane Vesicles (MVs) play important roles in cell-to-cell communication and transport of several molecules. Such structures are essential components of Extracellular Polymeric Substanc...","PeriodicalId":12314,"journal":{"name":"Expert Opinion on Therapeutic Patents","volume":"5 1","pages":""},"PeriodicalIF":6.6,"publicationDate":"2024-04-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140571165","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Synthetic lethality: targeting SMARCA2 ATPase in SMARCA4-deficient tumors – a review of patent literature from 2019–30 June 2023 合成致死：在SMARCA4缺陷肿瘤中靶向SMARCA2 ATP酶--2019年至2023年6月30日专利文献综述
IF 6.6 2区 医学
Expert Opinion on Therapeutic Patents Pub Date : 2024-04-05 DOI: 10.1080/13543776.2024.2338111
Kyle D. Reichl, Esther C. Y. Lee, Ariamala Gopalsamy
{"title":"Synthetic lethality: targeting SMARCA2 ATPase in SMARCA4-deficient tumors – a review of patent literature from 2019–30 June 2023","authors":"Kyle D. Reichl, Esther C. Y. Lee, Ariamala Gopalsamy","doi":"10.1080/13543776.2024.2338111","DOIUrl":"https://doi.org/10.1080/13543776.2024.2338111","url":null,"abstract":"The multi-subunit SWI/SNF chromatin remodeling complex is a key epigenetic regulator for many cellular processes, and several subunits are found to be mutated in human cancers. The inactivating mut...","PeriodicalId":12314,"journal":{"name":"Expert Opinion on Therapeutic Patents","volume":"5 1","pages":""},"PeriodicalIF":6.6,"publicationDate":"2024-04-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140571075","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
An overview on recent patents and technologies on nanoparticles for nucleic acid delivery 核酸递送纳米粒子最新专利和技术概览
IF 6.6 2区 医学
Expert Opinion on Therapeutic Patents Pub Date : 2024-04-05 DOI: 10.1080/13543776.2024.2338097
Larissa Moraes dos Santos Fonseca, Bruna Aparecida Souza Machado, Fabricia Oliveira Oliveira, Jânio Rodrigo de Jesus Santos, Jaqueline Wang da Silva, Katharine Valeria Saraiva Hodel, Brisa Gonçalves Rosatti, Claudio Damasceno Pinto, Milena Botelho Pereira Soares
{"title":"An overview on recent patents and technologies on nanoparticles for nucleic acid delivery","authors":"Larissa Moraes dos Santos Fonseca, Bruna Aparecida Souza Machado, Fabricia Oliveira Oliveira, Jânio Rodrigo de Jesus Santos, Jaqueline Wang da Silva, Katharine Valeria Saraiva Hodel, Brisa Gonçalves Rosatti, Claudio Damasceno Pinto, Milena Botelho Pereira Soares","doi":"10.1080/13543776.2024.2338097","DOIUrl":"https://doi.org/10.1080/13543776.2024.2338097","url":null,"abstract":"Nucleic acid-based therapeutics offer groundbreaking potential for treating genetic diseases and advancing next-generation vaccines. Despite their promise, challenges in efficient delivery persist ...","PeriodicalId":12314,"journal":{"name":"Expert Opinion on Therapeutic Patents","volume":"43 1","pages":""},"PeriodicalIF":6.6,"publicationDate":"2024-04-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140571149","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Targeting the relaxin-3/RXFP3 system: a patent review for the last two decades 以松弛素-3/RXFP3 系统为靶标：过去二十年的专利回顾
IF 6.6 2区 医学
Expert Opinion on Therapeutic Patents Pub Date : 2024-04-04 DOI: 10.1080/13543776.2024.2338099
Md Toufiqur Rahman, Hetti Handi Chaminda Lakmal, Javeena Hussain, Chunyang Jin
{"title":"Targeting the relaxin-3/RXFP3 system: a patent review for the last two decades","authors":"Md Toufiqur Rahman, Hetti Handi Chaminda Lakmal, Javeena Hussain, Chunyang Jin","doi":"10.1080/13543776.2024.2338099","DOIUrl":"https://doi.org/10.1080/13543776.2024.2338099","url":null,"abstract":"The neuropeptide relaxin-3/RXFP3 system belongs to the relaxin/insulin superfamily and is involved in many important physiological processes, such as stress responses, appetite control, and motivat...","PeriodicalId":12314,"journal":{"name":"Expert Opinion on Therapeutic Patents","volume":"59 1","pages":""},"PeriodicalIF":6.6,"publicationDate":"2024-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140571073","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信